Anadys Announces Appointment of Chief Scientific Officer and Board of Directors Member

- Steve Worland, Ph.D. (Chief Scientific Officer)

- Justin Hall-Tipping (Board of Directors)



Apr 23, 2001, 01:00 ET from Anadys Pharmaceuticals, Inc.

    SAN DIEGO, April 23 /PRNewswire Interactive News Release/ -- Anadys
 Pharmaceuticals, Inc. has named Steve Worland Chief Scientific Officer and
 Justin Hall-Tipping a new member of its  Board of Directors.
     Dr. Worland has a long career in both Biotechnology and the Pharmaceutical
 industries with comprehensive experience in discovery, development, and
 advancement of drugs to the clinic.  Dr. Worland was trained in chemistry at
 the University of California at Berkeley and then in molecular biology at
 Harvard University.  Dr. Worland was recruited to Agouron Pharmaceuticals
 where he held senior positions of increasing responsibility for 14 years at
 Agouron, Warner-Lambert, and Pfizer Pharmaceuticals, Inc..  Dr. Worland was
 most recently Vice President and global head of anti-infectives for Pfizer.
     "We are very happy to announce the appointment of Steve as our Chief
 Scientific Officer," said Kleanthis G. Xanthopoulos, Ph.D., President and
 Chief Executive Officer of Anadys Pharmaceuticals, Inc. "This appointment
 confirms our commitment to recruit only outstanding people to enhance our
 discovery development expertise.  Steve brings to Anadys over 14 years of
 biotechnology and pharmaceutical experience.  Most importantly, Steve has a
 strong track record of bringing compounds from early discovery all the way to
 the clinic, which is exactly what Anadys is focusing on through its integrated
 technologies and product portfolio," Dr. Xanthopoulos added.
     "I am very excited about working at Anadys," says Dr. Worland.  "It is
 rare to find a biotechnology company with such a strong and integrated biology
 and chemistry technology platform with the clear vision to get products into
 the clinic.  I am especially enthusiastic about the medicinal chemistry
 capabilities that Anadys brings to the table.  I am also excited to drive the
 Anadys platform in Riboproteomics, or RNA-protein interactions, as an untapped
 target class for therapeutic intervention.  The impressive speed with which
 Anadys has created this discovery engine reflects the drive and the vision of
 the organization as a whole, which is what attracted me to the company."
     Anadys also announced the election of Justin Hall-Tipping to the Board of
 Directors.   Justin Hall-Tipping is a Managing Director at SG Capital
 Partners. He joined SG from Reuters, where he was Director of the Data
 Intelligence Group.  Prior to this, he was CEO of HeartBeat Corp., a
 multimedia software company.  He was also a partner of the NEPA Venture Fund,
 which specialized in start-up and early stage companies.
     "The addition of Justin Hall-Tipping to our board brings to our company a
 valuable resource with experience across a wide spectrum of business sectors
 that are important to our growth," said Jason Fisherman, Chairman of the
 Board. " We are all looking forward to his involvement with Anadys."
     "I join the Anadys board with a tremendous amount of enthusiasm and
 respect for the challenges ahead," said Hall-Tipping. "The discovery,
 development, and advancement of medicines is perhaps the ultimate test of a
 team's strength, and I couldn't be more excited about the shared mission ahead
 and my role on the team."
 
     Anadys' Technology Platform
     Anadys' proprietary technologies bridge the biology-chemistry gap through
 screening, chemistry and bioinformatics services.  Anadys' proprietary
 technologies include GATE (Genetics Assisted Targeted Evaluation), which
 identifies and validates novel anti-infective targets; ATLAS (Any Target
 Ligand Affinity Screen) and SCAN (Screen for Compounds with Affinity for
 Nucleic Acids), which rapidly identify lead compounds that bind to protein or
 RNA targets even before the gene functions are well understood.  The unique
 tools allow researchers to work with targets that are unsuitable for
 traditional high-throughput assays.  Anadys' technologies also include a
 distinct high-throughput quality medicinal chemistry platform, and enable drug
 discovery research in Riboproteomics(TM), the emerging study of RNA-protein
 interactions.
 
     About Anadys Pharmaceuticals
     Anadys Pharmaceuticals is a drug discovery company employing proprietary
 technologies in microbial genomics, compound screening, medicinal chemistry
 and informatics to develop a portfolio of novel anti-infective products.  The
 company has two antiviral compounds in late preclinical development.  The
 company also plans to leverage its expertise to exploit the emerging field of
 Riboproteomics(TM), the study of RNA-protein interactions, for discovery of
 novel targets and therapeutic compounds.  For more information, please visit
 http://www.anadyspharma.com.
 
     About SG Capital Partners LLC
     SG Capital Partners LLC is the merchant banking affiliate of SG Cowen
 Securities Corp. which is a full service investment bank and dealer/broker
 with a strategic focus on high growth industries and particularly healthcare
 and technology. SG Capital Partners has a diverse portfolio of venture
 investments in the areas of telecommunications, technology and biotechnology.
 Recent investments in biotechnology include Ricerca LLC and Structural
 GenomiX, Inc. For more information visit http://www.sgcapitalpartners.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48880438
 
 

SOURCE Anadys Pharmaceuticals, Inc.
    SAN DIEGO, April 23 /PRNewswire Interactive News Release/ -- Anadys
 Pharmaceuticals, Inc. has named Steve Worland Chief Scientific Officer and
 Justin Hall-Tipping a new member of its  Board of Directors.
     Dr. Worland has a long career in both Biotechnology and the Pharmaceutical
 industries with comprehensive experience in discovery, development, and
 advancement of drugs to the clinic.  Dr. Worland was trained in chemistry at
 the University of California at Berkeley and then in molecular biology at
 Harvard University.  Dr. Worland was recruited to Agouron Pharmaceuticals
 where he held senior positions of increasing responsibility for 14 years at
 Agouron, Warner-Lambert, and Pfizer Pharmaceuticals, Inc..  Dr. Worland was
 most recently Vice President and global head of anti-infectives for Pfizer.
     "We are very happy to announce the appointment of Steve as our Chief
 Scientific Officer," said Kleanthis G. Xanthopoulos, Ph.D., President and
 Chief Executive Officer of Anadys Pharmaceuticals, Inc. "This appointment
 confirms our commitment to recruit only outstanding people to enhance our
 discovery development expertise.  Steve brings to Anadys over 14 years of
 biotechnology and pharmaceutical experience.  Most importantly, Steve has a
 strong track record of bringing compounds from early discovery all the way to
 the clinic, which is exactly what Anadys is focusing on through its integrated
 technologies and product portfolio," Dr. Xanthopoulos added.
     "I am very excited about working at Anadys," says Dr. Worland.  "It is
 rare to find a biotechnology company with such a strong and integrated biology
 and chemistry technology platform with the clear vision to get products into
 the clinic.  I am especially enthusiastic about the medicinal chemistry
 capabilities that Anadys brings to the table.  I am also excited to drive the
 Anadys platform in Riboproteomics, or RNA-protein interactions, as an untapped
 target class for therapeutic intervention.  The impressive speed with which
 Anadys has created this discovery engine reflects the drive and the vision of
 the organization as a whole, which is what attracted me to the company."
     Anadys also announced the election of Justin Hall-Tipping to the Board of
 Directors.   Justin Hall-Tipping is a Managing Director at SG Capital
 Partners. He joined SG from Reuters, where he was Director of the Data
 Intelligence Group.  Prior to this, he was CEO of HeartBeat Corp., a
 multimedia software company.  He was also a partner of the NEPA Venture Fund,
 which specialized in start-up and early stage companies.
     "The addition of Justin Hall-Tipping to our board brings to our company a
 valuable resource with experience across a wide spectrum of business sectors
 that are important to our growth," said Jason Fisherman, Chairman of the
 Board. " We are all looking forward to his involvement with Anadys."
     "I join the Anadys board with a tremendous amount of enthusiasm and
 respect for the challenges ahead," said Hall-Tipping. "The discovery,
 development, and advancement of medicines is perhaps the ultimate test of a
 team's strength, and I couldn't be more excited about the shared mission ahead
 and my role on the team."
 
     Anadys' Technology Platform
     Anadys' proprietary technologies bridge the biology-chemistry gap through
 screening, chemistry and bioinformatics services.  Anadys' proprietary
 technologies include GATE (Genetics Assisted Targeted Evaluation), which
 identifies and validates novel anti-infective targets; ATLAS (Any Target
 Ligand Affinity Screen) and SCAN (Screen for Compounds with Affinity for
 Nucleic Acids), which rapidly identify lead compounds that bind to protein or
 RNA targets even before the gene functions are well understood.  The unique
 tools allow researchers to work with targets that are unsuitable for
 traditional high-throughput assays.  Anadys' technologies also include a
 distinct high-throughput quality medicinal chemistry platform, and enable drug
 discovery research in Riboproteomics(TM), the emerging study of RNA-protein
 interactions.
 
     About Anadys Pharmaceuticals
     Anadys Pharmaceuticals is a drug discovery company employing proprietary
 technologies in microbial genomics, compound screening, medicinal chemistry
 and informatics to develop a portfolio of novel anti-infective products.  The
 company has two antiviral compounds in late preclinical development.  The
 company also plans to leverage its expertise to exploit the emerging field of
 Riboproteomics(TM), the study of RNA-protein interactions, for discovery of
 novel targets and therapeutic compounds.  For more information, please visit
 http://www.anadyspharma.com.
 
     About SG Capital Partners LLC
     SG Capital Partners LLC is the merchant banking affiliate of SG Cowen
 Securities Corp. which is a full service investment bank and dealer/broker
 with a strategic focus on high growth industries and particularly healthcare
 and technology. SG Capital Partners has a diverse portfolio of venture
 investments in the areas of telecommunications, technology and biotechnology.
 Recent investments in biotechnology include Ricerca LLC and Structural
 GenomiX, Inc. For more information visit http://www.sgcapitalpartners.com.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X48880438
 
 SOURCE  Anadys Pharmaceuticals, Inc.